课题基金 / 基金详情

Pathogenetic Mechanism for Hypersecretion of Mucin Glycoprotein in Cholelithiasis

Pathogenetic Mechanism for Hypersecretion of Mucin Glycoprotein in Cholelithiasis
胆石症粘蛋白糖蛋白分泌过多的发病机制
批准号:
09670509
负责人:
SHODA Junichi
金额:
$2.05万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1997
资助国家:
日本
项目状态:
已结题
起止时间:
1997 至 1999

项目摘要

项目成果

SHODA Junichi的其他基金

相似基金

相关文献

中文摘要
翻译
Multiple cholesterol stones are associated with more biliary complications and exhibit more rapid cholesterol nucleation than solitary stones。Secretory or group II phospholipase A I D22文件D2(PLA D 22文件D2-II)levels in gallbladder bile were significantly higher in patients with multiple cholesterol stones than in those with solitary stones or control subjects.Increased biliary PLA I D22 ii D2-II levels in multiple cholesterol stones were associated with a concomitant increase in the protein and hexosamine concentrations as well as gallbladder bile viscosity.Increased PLA锡D22文件D2-II in gallbladder bile may be of pathogenetic importance in patients with multiple cholesterol stones,probably through potentiating gallbladder mucosal inflammation with associated biliary alterations favoring cholesterol crystal formation.Ursodeoxycholate(UDC)decreases biliary levels of various pronucleating proteins,possibly due to its mbremane-protective decreases biliary levels of various pronucleating proteinsLong-te…More rm UDC administration was observed to lower the increased PLA I D22文件D2-II protein mass and mRNA level as well as the PLA I D 22文件D2-V mRNA level in the gallbladders of patients with multiple cholesterol stones,which in turn may be of therapeutic importance in improving the gallbladder mucosal inflammation.Effects of UDC on secretory low molecular weight PLA I D22个D2s as inflammatory mediators may relate to the reported efficacy of UDC treatment in cholesterol gallstone disease.Intrahepatic calculi is characterized by an intractable course and frequent recurrences.Chronic proliferative cholangitis may underlie the complex nature of the disease.PLA I D22 ii D2-II levels were significantly higher in the bile from the stone-containing hepatic ducts than in the ductal bile from gallbladder stone patients.The increased sPLA I D22文件D2 levels were associated with a concomitant increase in prostaglandin E I D22文件D2 and total mucin concentrations.The affected bile ducts showed an increased mRNA level of PLA I D22文件D2-II compared with the ducts from control subjects.In intrahepatic calculi,an enhanced expression of the PLA I D22 ii D2-II may be of pathophysiological significance for the chronic proliferative cholangitis,probably through biliary alterations favoring growth of preexisting stones and even further progressions。Less:Less
英文摘要
Multiple cholesterol stones are associated with more biliary complications and exhibit more rapid cholesterol nucleation than solitary stones. Secretory or group II phospholipase AィイD22ィエD2 (PLAィイD22ィエD2-II) levels in gallbladder bile were significantly higher in patients with multiple cholesterol stones than in those with solitary stones or control subjects. Increased biliary PLAィイD22ィエD2-II levels in multiple cholesterol stones were associated with a concomitant increase in the protein and hexosamine concentrations as well as gallbladder bile viscosity. Increased PLAィイD22ィエD2-II in gallbladder bile may be of pathogenetic importance in patients with multiple cholesterol stones, probably through potentiating gallbladder mucosal inflammation with associated biliary alterations favoring cholesterol crystal formation.Ursodeoxycholate (UDC) decreases biliary levels of various pronucleating proteins, possibly due to its membrane-protective effects on the inflamed gallbladder mucosa. Long-te … More rm UDC administration was observed to lower the increased PLAィイD22ィエD2-II protein mass and mRNA level as well as the PLAィイD22ィエD2-V mRNA level in the gallbladders of patients with multiple cholesterol stones, which in turn may be of therapeutic importance in improving the gallbladder mucosal inflammation. Effects of UDC on secretory low molecular weight PLAィイD22ィエD2s as inflammatory mediators may relate to the reported efficacy of UDC treatment in cholesterol gallstone disease.Intrahepatic calculi is characterized by an intractable course and frequent recurrences. Chronic proliferative cholangitis may underlie the complex nature of the disease. PLAィイD22ィエD2-II levels were significantly higher in the bile from the stone-containing hepatic ducts than in the ductal bile from gallbladder stone patients. The increased sPLAィイD22ィエD2 levels were associated with a concomitant increase in prostaglandin EィイD22ィエD2 and total mucin concentrations. The affected bile ducts showed an increased mRNA level of PLAィイD22ィエD2-II compared with the ducts from control subjects. In intrahepatic calculi, an enhanced expression of the PLAィイD22ィエD2-II may be of pathophysiological significance for the chronic proliferative cholangitis, probably through biliary alterations favoring growth of preexisting stones and even further progressions. Less
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Shoda J: "Simultaneous determination of plasma mevalonate and 7α-hydroxy-4-cholesten-3-one levels in hyperlipoproteinemia" Hepatology. 25. 18-26 (1997)
Shoda J:“高脂蛋白血症中血浆甲羟戊酸和 7α-羟基-4-胆固醇-3-酮水平的同时测定”《肝病学》25. 18-26 (1997)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Kano, M., Shoda, J., Irimura, T., Ueda, T., Iwasaki, R., Urasaki, T., Kawauchi, Y., Asano, T., Matsuzaki, Y., Tanaka, N.: "Effects of long-term ursodeoxycholate administration on expression levels of secretory low molecular weight phospholipase AィイD22ィエD2
Kano, M.、Shoda, J.、Irimura, T.、Ueda, T.、Iwasaki, R.、Urasaki, T.、Kawauchi, Y.、Asano, T.、Matsuzaki, Y.、Tanaka, N.: “长期给予熊去氧胆酸对分泌型低分子量磷脂酶 A-D22-D2 表达水平的影响
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Tomida S.et al.: "Long-term ursodeoxycholic acid therapy is〜"Hepatology. 30. 6-13 (1999)
Tomida S. 等人:“长期熊去氧胆酸治疗是~”《肝病学》30. 6-13 (1999)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Shoda J,et al.: "Secretory low-molecular-weight phospholipase A2 and their specific receptor in bile ducts of patients with intrahepatic calculi: factors of chronic proliferative cholalngitis" Hepatology. 29(in press). (1999)
Shoda J等人:“肝内结石患者胆管中的分泌性低分子量磷脂酶A2及其特异性受体:慢性增殖性胆管炎的因素”肝病学。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
共 16 条
    Improvement of metabolic and exercise function of skeletal muscles through activation of transcription factor, and prevention of obesity-related liver disease
    • 批准号:
      23300250
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $12.48万
    • 财政年份:
      2011
    • 负责人:
      SHODA Junichi
    • 依托单位:
    Inhibitory effects of exercise on progression of obesity-related liver diseases and development of glyco-biomarkers to scale the pathophysiology of the liver diseases
    • 批准号:
      22650162
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.07万
    • 财政年份:
      2010
    • 负责人:
      SHODA Junichi
    • 依托单位:
    Development of novel cytotoxin therapy that targets tumor-associated surface molecules of biliary tract carcinoma
    • 批准号:
      20390339
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $12.48万
    • 财政年份:
      2008
    • 负责人:
      SHODA Junichi
    • 依托单位:
    Analysis of mucin glycoproteins in the gallbladder of BK5.erbB2 transgenic mouse
    • 批准号:
      15590618
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.24万
    • 财政年份:
      2003
    • 负责人:
      SHODA Junichi
    • 依托单位:
    国内基金
    海外基金
    Mucin蛋白在泌丝动物家蚕和蜘蛛中的功能研究
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
      郭凯雨
    • 依托单位:
    维生素D受体通过抑制Mucin-1/β1-integrin信号通路调节肠道衰老的相关机制研究
    肠粘蛋白mucin介导的中肠黏膜屏障在蜜蜂感染囊状幼虫病毒 ( SBV )差异性的作用研究
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2024
    • 负责人:
      党晓群
    • 依托单位:
    黏蛋白1(Mucin1)在脓毒症ALI/ARDS铁死亡发生过程中的作用和机制研究
    • 批准号:
      82300106
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      30万元
    • 批准年份:
      2023
    • 负责人:
      王聿明
    • 依托单位: